BioMarin Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Alexander Hardy
Chief executive officer
US$18.6m
Total compensation
| CEO salary percentage | 0.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.01% |
| Management average tenure | 3.2yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensation vs Market: Alexander's total compensation ($USD18.59M) is above average for companies of similar size in the US market ($USD12.85M).
Compensation vs Earnings: Insufficient data to compare Alexander's compensation with company performance.
CEO
Alexander Hardy (55 yo)
less than a year
Tenure
US$18,586,001
Compensation
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$18.59m | 0.0099% $ 1.2m | |
| CFO & Executive VP | 4.9yrs | US$4.85m | 0.038% $ 4.7m | |
| Executive VP & CTO | no data | US$5.70m | 0.012% $ 1.5m | |
| Advisor | 8.2yrs | US$9.66m | 0.097% $ 12.2m | |
| Group VP & Chief Accounting Officer | 2.6yrs | no data | 0.00071% $ 88.8k | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | no data | no data | |
| Group Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 20.9yrs | US$5.19m | 0.029% $ 3.7m | |
| Senior VP & Chief Marketing Officer | 2.6yrs | no data | no data | |
| Executive VP & Chief People Officer | 5.9yrs | no data | no data | |
| Senior Vice President of Technical Development | 3.2yrs | no data | no data | |
| Executive VP & Chief Corporate Affairs Officer | less than a year | no data | no data |
3.2yrs
Average Tenure
54yo
Average Age
Experienced Management: BMRN's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$18.59m | 0.0099% $ 1.2m | |
| Independent Chairman of the Board | 18yrs | US$515.44k | 0.060% $ 7.5m | |
| Independent Director | 8.9yrs | US$470.44k | 0.021% $ 2.7m | |
| Independent Director | less than a year | US$213.38k | no data | |
| Independent Director | 22.4yrs | US$486.44k | 0.049% $ 6.1m | |
| Independent Director | 8.4yrs | US$480.44k | 0.012% $ 1.5m | |
| Independent Director | 3.8yrs | US$473.94k | 0.0065% $ 817.1k | |
| Independent Director | 7.3yrs | US$486.94k | 0.014% $ 1.7m | |
| Independent Director | less than a year | US$213.38k | no data | |
| Independent Director | 5.4yrs | US$480.44k | 0.0099% $ 1.2m | |
| Independent Director | less than a year | US$213.38k | no data |
5.4yrs
Average Tenure
64yo
Average Age
Experienced Board: BMRN's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 22:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 57 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |